Elutia Inc
NASDAQ:ELUT

Watchlist Manager
Elutia Inc Logo
Elutia Inc
NASDAQ:ELUT
Watchlist
Price: 4.38 USD -9.5% Market Closed
Market Cap: 151.4m USD
Have any thoughts about
Elutia Inc?
Write Note

Elutia Inc
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Elutia Inc
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
Elutia Inc
NASDAQ:ELUT
Capital Expenditures
-$346k
CAGR 3-Years
19%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Capital Expenditures
-$888m
CAGR 3-Years
0%
CAGR 5-Years
-12%
CAGR 10-Years
-4%
Gilead Sciences Inc
NASDAQ:GILD
Capital Expenditures
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Capital Expenditures
-$974m
CAGR 3-Years
-8%
CAGR 5-Years
-8%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Capital Expenditures
-$508.9m
CAGR 3-Years
-32%
CAGR 5-Years
-47%
CAGR 10-Years
-26%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Capital Expenditures
-$928.1m
CAGR 3-Years
-18%
CAGR 5-Years
-20%
CAGR 10-Years
-13%
No Stocks Found

Elutia Inc
Glance View

Market Cap
151.4m USD
Industry
Biotechnology

Aziyo Biologics, Inc. operates as a biotechnology company. The company is headquartered in Silver Spring, Maryland and currently employs 151 full-time employees. The company went IPO on 2020-10-08. The firm is a commercial-stage company that serves two markets with products based on its biomatrix platforms. The company offers a drug-eluting biologic technology: a fusion of natural biologic material and extended antibiotic release, for device implantation and soft tissue reconstruction. Its first product is CanGaroo Envelope, used for the stabilization of implantable cardiac devices, such as pacemakers and defibrillators. Its second product is SimpliDerm Acellular Dermal Matrix, used primarily in breast reconstruction following mastectomy. The company is also engaged in the development of CanGaroo RM, which adds the antibiotics rifampin and minocycline for sustained delivery directly to the surgical site. The Company’s products are used by electrophysiologists and plastic surgeons.

ELUT Intrinsic Value
6.79 USD
Undervaluation 35%
Intrinsic Value
Price

See Also

What is Elutia Inc's Capital Expenditures?
Capital Expenditures
-346k USD

Based on the financial report for Dec 31, 2023, Elutia Inc's Capital Expenditures amounts to -346k USD.

What is Elutia Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-13%

Over the last year, the Capital Expenditures growth was 36%. The average annual Capital Expenditures growth rates for Elutia Inc have been 19% over the past three years , -13% over the past five years .

Back to Top